TickerGuard
Buy Day today: Neutral (48) Mixed market breadth · no major macro event
MYGN

Myriad Genetics Inc

Healthcare · Diagnostics & Research

4.20$ +1.7% vs. previous close Closing price · As of: Sep 28, 2026

Statements

Income Statement

Myriad Genetics Inc (MYGN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 191 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement MYGN
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
192 197 202 212 213 211 196 213 206 210 200 191 807
58 62 65 64 64 60 62 61 62 63 63 64 251
134 135 138 147 150 151 134 152 144 147 138 127 555
24 21 25 27 29 32 28 26 28 26 27 25 106
136 33 71 72 69 148 67 67 68 56 62 58 244
194 166 166 184 170 190 163 481 167 153 168 166 654
-60 -31 -28 -37 -20 -39 -29 -329 -23 -5.7 -31 -39 -99
1.0 0.9 0.5 0.8 0.8 0.7 0.8 1.5 3.8 4.4 4.1 4.1 16
-61 -32 -26 -37 -21 -39 -29 -331 -26 -8.9 -34 -43 -112
0.1 -1.1 0.1 -0.5 0.9 3.4 -29 -0.1 1.2 -1.0 – 0.6 –
-61 -31 -26 -37 -22 -43 -0.1 -331 -27 -7.9 -34 -43 -113
-46 -16 -9.7 -21 -4.8 -24 -14 -315 -9.8 8.1 -18 -26 -45

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?